A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
about
The value of trabectedin in the treatment of soft tissue sarcomaAlkaloids from marine invertebrates as important leads for anticancer drugs discovery and developmentA systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcomaNew developments in treatment of ovarian carcinoma: focus on trabectedinClinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Overcoming platinum resistance in ovarian carcinoma.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialTrabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Estrogen biosynthesis and action in ovarian cancer.Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerEmerging role of pemetrexed in ovarian cancer.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Current status of bevacizumab in advanced ovarian cancerPhase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesTrabectedin: an anticancer drug from the sea.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?The efficacy of trabectedin in treating ovarian cancer.Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
P2860
Q26772855-219C22E1-8B87-4824-A296-E137DB72267CQ27012072-953E7A10-CA6E-42BF-8D5E-EF2D1EB98506Q28482357-7A7D12BD-DA35-47A0-9872-693F5D09BD30Q33393429-5E5A35DF-5F3D-45A7-941B-E56D4D1490B0Q33921802-06FB6017-D570-4237-AFDC-1674B00D3AEEQ34233273-C7949404-B8BB-49E9-B3B3-587ADE08DDD7Q34413664-93D1DB13-D53E-4417-B61E-2B4FC97997D9Q34413670-8FC45875-6D3D-4614-A5AC-6BFC60DDF19DQ34496401-A906376D-5E36-4ECD-84B7-3E73626D636BQ34650482-BD27B99F-EB13-479A-9C00-61C225287BBDQ34721579-12B8467B-024D-400F-B92D-7581E1B21802Q34736667-FB5EC34E-38F6-4251-BB23-93FC5C2B91B7Q34996149-8CBC3A27-8FAD-4A2E-AC49-5251FA161736Q35015611-E1A51E81-53EC-4C95-9772-3355EE5764C4Q35088311-A37A8594-1F3F-4618-86BD-F444BC0A5AA8Q37048186-D3492066-0506-49D2-86EF-3BE0A69E75C8Q37163139-820C3F4C-81EE-49E0-BCAA-EFCFD24A234CQ37594790-626D6EC7-347D-4F3A-B31E-2A73C9F91B60Q37760957-B998B112-247C-4A2F-9E18-AA18F5D5A34AQ37765581-930D0283-10A9-4CC6-82B4-E7100DE9A711Q37809986-E08F1BA9-5E70-436B-85EF-E5D7A2AD7E3BQ37854494-6401B735-5AFF-4BB6-9032-2355FF03FD64Q38693066-2BFE7C08-F763-448F-9732-C95631A1F778Q38763841-4EDB16A1-3C2C-4E7C-9350-F01B1463C93BQ39497253-5EDC749B-61E8-47EB-94E3-94C4FE298B08Q47885855-4E516ED9-C661-4BA7-91AC-9ED663BE97A3Q55365628-84061720-D55E-45E3-8CC2-1ACBFDA094BFQ57570787-1CF730AB-C462-47D8-B145-6620B226A9CD
P2860
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A Phase II study of trabectedi ...... with platinum-based regimens.
@ast
A Phase II study of trabectedi ...... with platinum-based regimens.
@en
type
label
A Phase II study of trabectedi ...... with platinum-based regimens.
@ast
A Phase II study of trabectedi ...... with platinum-based regimens.
@en
prefLabel
A Phase II study of trabectedi ...... with platinum-based regimens.
@ast
A Phase II study of trabectedi ...... with platinum-based regimens.
@en
P2093
P2860
P356
P1476
A Phase II study of trabectedi ...... with platinum-based regimens.
@en
P2093
C N Krasner
D M Provencher
D S McMeekin
F G Renshaw
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604088
P407
P577
2007-11-13T00:00:00Z